by Heidi Hagen and Christophe Suchet | December 4, 2019
This post is the first in an eight-part series on data management strategies for personalized therapeutics, such as cell therapies, gene therapies, or neoantigen cancer vaccines.
by Louis Rawlins | November 26, 2019
More and more of today’s healthcare happens online, but digital is just one part of the picture. Much of the success -- or failure -- of digital tools is highly dependent on what happens beyond the screen or device, in the services and human…
by Marc Puich | November 15, 2019
At Biomanufacturing World Summit this week, leaders at the forefront of producing cell and gene therapies gathered to talk about what’s really required to produce deeply individualized therapeutics at scale. Here are a few of the highlights:
by Amy DuRoss | November 6, 2019
Today, Vineti is excited to announce a new partnership with a global contract manufacturing company serving cell therapies and gene therapies -- and not just because this represents growth for our company. We’re excited because this alignment, and…
Chain of Identity and Chain of Custody in personalized therapies -- core differences from traditional pharma
by Heidi Hagen | October 30, 2019
In pharmaceutical manufacturing, Chain of Identity and Chain of Custody may not be new -- but in advanced therapy manufacturing, they take on a whole new significance. Why? Because in personalized therapies, a person is a key part of the process.